

Highlights of This Issue 4683

SPECIAL FEATURES

CCR Translations

- 4685 | **Location, Location, Location-Makes All the Difference for Hypoxia in Lung Tumors**
Amit Maity and Constantinos Koumenis
See article p. 4843

CCR New Strategies

- 4688 | **New Strategies in Hepatocellular Carcinoma: Genomic Prognostic Markers**
Augusto Villanueva, Yujin Hoshida, Sara Toffanin, Anja Lachenmayer, Clara Alsinet, Radoslav Savic, Helena Cornella, and Josep M. Llovet

Molecular Pathways

- 4695 | **Wnt/ β -Catenin Signaling in T-Cell Immunity and Cancer Immunotherapy**
Luca Gattinoni, Yun Ji, and Nicholas P. Restifo

Review

- 4702 | **Poly(ADP-Ribose) Polymerase Inhibition: "Targeted" Therapy for Triple-Negative Breast Cancer**
Carey K. Anders, Eric P. Winer, James M. Ford, Rebecca Dent, Daniel P. Silver, George W. Sledge, and Lisa A. Carey

HUMAN CANCER BIOLOGY

- 4711 | **Involvement of Human Herpesvirus-6 Variant B in Classic Hodgkin's Lymphoma via DR7 Oncoprotein**
Aurélie Lacroix, Sophie Collot-Teixeira, Laurent Mardivirin, Arnaud Jaccard, Barbara Petit, Christophe Piguet, Franck Sturtz, Pierre-Marie Preux, Dominique Bordessoule, and Sylvie Ranger-Rogez

- 4722 | **Comprehensive Analysis of the MYB-NFIB Gene Fusion in Salivary Adenoid Cystic Carcinoma: Incidence, Variability, and Clinicopathologic Significance**
Yoshitsugu Mitani, Jie Li, Pulivarthi H. Rao, Yi-Jue Zhao, Diana Bell, Scott M. Lippman, Randal S. Weber, Carlos Caulin, and Adel K. El-Naggar

- 4732 | **Hypoxia Inducible Factor 1 α and Hypoxia Inducible Factor 2 α Play Distinct and Functionally Overlapping Roles in Oral Squamous Cell Carcinoma**
Gui-quan Zhu, Ya-ling Tang, Ling Li, Min Zheng, Jian Jiang, Xiao-yu Li, Si-xiu Chen, and Xin-hua Liang

CANCER THERAPY: PRECLINICAL

- 4742 | **Role of CAAT/Enhancer Binding Protein Homologous Protein in Panobinostat-Mediated Potentiation of Bortezomib-Induced Lethal Endoplasmic Reticulum Stress in Mantle Cell Lymphoma Cells**
Rekha Rao, Srilatha Nalluri, Warren Fiskus, Andrew Savoie, Kathleen M. Buckley, Kyungsoo Ha, Ramesh Balusu, Atul Joshi, Veena Coothankandaswamy, Jianguo Tao, Eduardo Sotomayor, Peter Atadja, and Kapil N. Bhalla

- 4755 | **Mitochondrial-Mediated Apoptosis in Lymphoma Cells by the Diterpenoid Lactone Andrographolide, the Active Component of *Andrographis paniculata***
Shuo Yang, Andrew M. Evens, Sheila Prachand, Amareshwar T.K. Singh, Savita Bhalla, Kevin David, and Leo I. Gordon

4769 **Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer**

Jagath R. Junutula, Kelly M. Flagella, Richard A. Graham, Kathryn L. Parsons, Edward Ha, Helga Raab, Sunil Bhakta, Trung Nguyen, Debra L. Dugger, Guangmin Li, Elaine Mai, Gail D. Lewis Phillips, Hajime Hiraragi, Reina N. Fuji, Jay Tibbitts, Richard Vandlen, Susan D. Spencer, Richard H. Scheller, Paul Polakis, and Mark X. Sliwkowski

4779 **Preclinical Characterization of Mitochondria-Targeted Small Molecule Hsp90 Inhibitors, Gamitrinibs, in Advanced Prostate Cancer**

Byoung Heon Kang, Markus D. Siegelin, Janet Plescia, Christopher M. Raskett, David S. Garlick, Takehiko Dohi, Jane B. Lian, Gary S. Stein, Lucia R. Languino, and Dario C. Altieri

4789 **Cisplatin-Induced Downregulation of OCTN2 Affects Carnitine Wasting**

Cynthia S. Lancaster, Chaoxin Hu, Ryan M. Franke, Kelly K. Filipinski, Shelley J. Orwick, Zhaoyuan Chen, Zhili Zuo, Walter J. Loos, and Alex Sparreboom

4800 **Superior Efficacy of Tumor Cell Vaccines Grown in Physiologic Oxygen**

Michael R. Olin, Brian M. Andersen, David M. Zellmer, Patrick T. Grogan, Flavia E. Popescu, Zhengming Xiong, Colleen L. Forster, Charlie Seiler, Karen S. SantaCruz, Wei Chen, Bruce R. Blazar, and John R. Ohlfest

4809 **Tumor Regression and Curability of Preclinical Neuroblastoma Models by PEGylated SN38 (EZN-2208), a Novel Topoisomerase I Inhibitor**

Fabio Pastorino, Monica Loi, Puja Sapra, Pamela Becherini, Michele Cilli, Laura Emionite, Domenico Ribatti, Lee M. Greenberger, Ivan D. Horak, and Mirco Ponzoni

4822 **Detailed Distribution of NK012, an SN-38-Incorporating Micelle, in the Liver and Its Potent Antitumor Effects in Mice Bearing Liver Metastases**

Amane Takahashi, Nobuhiro Ohkohchi, Masahiro Yasunaga, Jun-ichiro Kuroda, Yoshikatsu Koga, Hirotsugu Kenmotsu, Taira Kinoshita, and Yasuhiro Matsumura

4832 **Phase I Pharmacokinetic and Pharmacodynamic Evaluation of Combined Valproic Acid/Doxorubicin Treatment in Dogs with Spontaneous Cancer**

Luke A. Wittenburg, Daniel L. Gustafson, and Douglas H. Thamm

IMAGING, DIAGNOSIS, PROGNOSIS

4843 **Hypoxia in Models of Lung Cancer: Implications for Targeted Therapeutics**

Edward E. Graves, Marta Vilalta, Ivana K. Cecic, Janine T. Erler, Phuoc T. Tran, Dean Felsher, Leanne Sayles, Alejandro Sweet-Cordero, Quynh-Thu Le, and Amato J. Giaccia
See commentary p. 4685

4853 **Biomarkers Predicting Outcome in Patients with Advanced Renal Cell Carcinoma: Results from Sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial**

Carol Peña, Chetan Lathia, Minghua Shan, Bernard Escudier, and Ronald M. Bukowski

4864 **Lung Squamous Cell Carcinoma mRNA Expression Subtypes Are Reproducible, Clinically Important, and Correspond to Normal Cell Types**

Matthew D. Wilkerson, Xiaoying Yin, Katherine A. Hoadley, Yufeng Liu, Michele C. Hayward, Christopher R. Cabanski, Kenneth Muldrew, C. Ryan Miller, Scott H. Randell, Mark A. Socinski, Alden M. Parsons, William K. Funkhouser, Carrie B. Lee, Patrick J. Roberts, Leigh Thorne, Philip S. Bernard, Charles M. Perou, and D. Neil Hayes

CANCER THERAPY: CLINICAL

4876 **Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors**

José Baselga, Andres Cervantes, Erika Martinelli, Isabel Chirivella, Klaas Hoekman, Herbert I. Hurwitz, Duncan I. Jodrell, Paul Hamberg, Esther Casado, Paul Elvin, Alan Swaisland, Renee Iacona, and Josep Tabernero

4884 | **Efficacy of Imatinib in Aggressive Fibromatosis: Results of a Phase II Multicenter Sarcoma Alliance for Research through Collaboration (SARC) Trial**

Rashmi Chugh, J. Kyle Wathen, Shreyaskumar R. Patel, Robert G. Maki, Paul A. Meyers, Scott M. Schuetze, Dennis A. Priebat, Dafydd G. Thomas, Jon A. Jacobson, Brian L. Samuels, Robert S. Benjamin, and Laurence H. Baker; for Sarcoma Alliance for Research through Collaboration (SARC)

4892 | **Successful Treatment of Melanoma Brain Metastases with Adoptive Cell Therapy**


Jenny J. Hong, Steven A. Rosenberg, Mark E. Dudley, James C. Yang, Donald E. White, John A. Butman, and Richard M. Sherry

4899 | **Inhibition of Carboplatin-Induced DNA Interstrand Cross-link Repair by Gemcitabine in Patients Receiving these Drugs for Platinum-Resistant Ovarian Cancer**

Jonathan A. Ledermann, Hani Gabra, Gordon C. Jayson, Victoria J. Spanswick, Gordon J.S. Rustin, Mark Jital, Lindsay E. James, and John A. Hartley

ABOUT THE COVER

Preclinical toxicology analysis of Gamitrinibs. Animals carrying prostate cancer xenografts and treated systemically with vehicle or Gamitrinib-TPP (G-TPP) were sacrificed at the end of treatment and organs were collected and analyzed histologically. A representative image of spleen from the vehicle group is shown. For further details, please see the article by Kang and colleagues on page 4779 of this issue.



Clinical Cancer Research

16 (19)

Clin Cancer Res 2010;16:4683-4905.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/16/19>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/16/19>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.